Company intelligence / Profile preview

NMT Pharmaceuticals

Singapore

Ownership: Private
Development stage: Other

Overview

NMT Pharmaceuticals is developing small molecule therapeutics with a focus on the micro- and nano-drug delivery platform. Their most advanced asset (CZ-48) targets Topoisomerase I for hematological malignancies and has reached preclinical/early regulatory review; another asset (CZ-150729) for neoplasms was discontinued[4].

Therapeutic areas: Oncology
Modalities: Small moleculeNano drug delivery
Industry: Biotech

Partnerships

Cao Pharmaceuticals (USA) (licensing of CZ-48)[7]

Beyond the preview

Go deeper on NMT Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NMT Pharmaceuticals.

Explore the full profile